Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Optherion Inc.

This article was originally published in Start Up

Executive Summary

Based on a growing understanding of the genetics of age-related macular degeneration and its association with the immune system, Optherion is developing a treatment that it hopes may prevent the disease from progressing into its most serious and debilitating 'wet' form.

You may also be interested in...



Venture Eyes Ophthalmology--And Likes What It Sees

Ophthalmology has long been a bright spot for venture investors given the potential market size, health care burden, and high unmet medical need associated with many eye diseases. Based on a recent analysis by Start-Up magazine, there is no sign that trend is diminishing. Using Elsevier's Strategic Transactions database, Start-Up found that private backers have poured nearly $1.8 billion into 58 ophthalmology start-ups since 1999, with the money split nearly 50/50 in terms of device and drug investments. This trend is likely to accelerate as a number of new acquirers emerge to play in what was once a niche area.

Acucela Inc.

Acucela is developing oral compounds that can possibly slow or stop vision loss caused by dry age-related macular degeneration. Its lead candidate is a small-molecule inhibitor of an enzyme called RPE65, known to be involved in the build-up of A2E, a toxic vitamin A by-product that is implicated in AMD.

Sirion Therapeutics Inc.

Fenretinide, Sirion Therapeutics' lead candidate, targets the pathway by which Vitamin A gets into the eye and becomes part of A2E, the protein complex that scientists consider a bad actor in AMD. Intermediate analysis of fenretinide Phase II data showed that patients taking the compound had slower growth of lesions than those given placebo, and that trend increased over time.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

WI964834

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel